Long Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Long Yuan has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Anne-Françoise Aubry
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb, Princeton, NJ 08543, USA
12 shared publicationsQin C Ji
Nonclinical Disposition & Bioanalysis, Bristol Myers Squibb, Princeton, NJ08543, USA
8 shared publicationsJianing Zeng
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Co, Route 206 and Province Line Road, Princeton, NJ, 08543, USA
6 shared publicationsMark E. Arnold
Analytical and Bioanalytical Development, Bristol-Myers Squibb, Princeton NJ 08543, United States
6 shared publications- Qin C. Ji
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA
6 shared publications Duxi Zhang
Analytical and Bioanalytical Development, Research & Development, Bristol-Myers Squibb, Princeton, NJ 08543, USA
4 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (6) , 153
Impact of Extraction Recovery and Matrix Effect on qPCR-based Biodistribution Analysis in Gene Therapy: Strategies for Mitigation
In DNA biodistribution studies, genomic DNA (gDNA) is commonly used as a normalizer for quantifying vector DNA (vDNA) to account for multiple variations in
- 18 September 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (6) , 153
Open AccessImpact of Extraction Recovery and Matrix Effect on qPCR-based Biodistribution Analysis in Gene Therapy: Strategies for Mitigation
In DNA biodistribution studies, genomic DNA (gDNA) is commonly used as a normalizer for quantifying vector DNA (vDNA) to account for multiple variations in
- 2 September 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (12-13) , 1183-1196
Recent developments in microsampling for oligonucleotides and biologics bioanalysis
1. For decades, therapeutic modalities were dominated by small molecule drugs, characterized by favorable properties, low molecular weight, and predictable pharmacokinetic profiles. However, the in...
- 2 September 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (12-13) , 1183-1196
Recent developments in microsampling for oligonucleotides and biologics bioanalysis
1. For decades, therapeutic modalities were dominated by small molecule drugs, characterized by favorable properties, low molecular weight, and predictable pharmacokinetic profiles. However, the in...
- Open Access
- 28 May 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1416, 345757
Hybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates
- 28 May 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1416, 345757
Open AccessHybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (4) , 355-366
Overcoming inconsistent DNA extraction recovery across tissue types in qPCR assays supporting biodistribution studies
1. Over the past decade, cell and gene therapy has emerged as a prominent area in drug discovery and development, because it provides new, durable treatment options for multiple indications, such a...
- 4 March 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (4) , 355-366
Open AccessOvercoming inconsistent DNA extraction recovery across tissue types in qPCR assays supporting biodistribution studies
1. Over the past decade, cell and gene therapy has emerged as a prominent area in drug discovery and development, because it provides new, durable treatment options for multiple indications, such a...
- Open Access
- 27 November 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1766, 466575
Hybridization liquid chromatography-mass spectrometry for quantitative bioanalysis of oligonucleotides: The upcoming paradigm shift
- 27 November 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1766, 466575
Open AccessHybridization liquid chromatography-mass spectrometry for quantitative bioanalysis of oligonucleotides: The upcoming paradigm shift
- Open Access
- 1 September 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (36) , 19570-19577
A Novel Hybrid LC-MS/MS Methodology for the Quantitative Bioanalysis of Antibody-siRNA Conjugates
Small interfering RNA (siRNA) is a new class of oligonucleotide therapeutics that is rapidly growing in drug research and development for the treatment of various diseases. One major challenge for siRNA therapeutics is their inefficient delivery to target tissues by systemic administration. Antibody-siRNA conjugates (ARC) are being developed as a promising approach to enhancing the selectivity and delivery of siRNA payloads to target tissues. A sensitive, selective, and reliable method to quantify ARCs in biological samples is critical to understand their pharmacokinetics, pharmacodynamics, toxicity, and biodistribution properties. There are very limited methods reported for the quantification of ARCs, including reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or hybridization enzyme linked immunosorbent assay (hELISA); however, these methods were still proof-of-concept or suffered from poor specificity or assay performance. LC-MS/MS has been used for the quantification of various modalities, including siRNA or oligonucleotides. The technique offers unique advantages of high specificity, fast method development, and robust assay performance. However, no LC-MS/MS-based method has been reported for the quantitative bioanalysis of ARCs. In this work, we developed a novel hybrid LC-MS/MS methodology for the quantification of ARCs using Ab-siRNA01, an antibody-siRNA conjugate, as the test compound. An antihuman IgG antibody was used as the capture antibody to selectively extract the target ARC analyte from the serum samples. The optimized hybrid LC-MS/MS method was successfully qualified for the quantitation of Ab-siRNA01 in mouse serum over the range of 6.70-3350 ng/mL. The developed method was used to support pharmacokinetic studies of Ab-siRNA01 in mice. This work is the first instance where a hybrid LC-MS/MS method was developed and applied to the quantification of antibody-siRNA conjugates. This novel methodology can also be applied to other ARCs and significantly facilitates their research and development.
- 1 September 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (36) , 19570-19577
Open AccessA Novel Hybrid LC-MS/MS Methodology for the Quantitative Bioanalysis of Antibody-siRNA Conjugates
Small interfering RNA (siRNA) is a new class of oligonucleotide therapeutics that is rapidly growing in drug research and development for the treatment of various diseases. One major challenge for siRNA therapeutics is their inefficient delivery to target tissues by systemic administration. Antibody-siRNA conjugates (ARC) are being developed as a promising approach to enhancing the selectivity and delivery of siRNA payloads to target tissues. A sensitive, selective, and reliable method to quantify ARCs in biological samples is critical to understand their pharmacokinetics, pharmacodynamics, toxicity, and biodistribution properties. There are very limited methods reported for the quantification of ARCs, including reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or hybridization enzyme linked immunosorbent assay (hELISA); however, these methods were still proof-of-concept or suffered from poor specificity or assay performance. LC-MS/MS has been used for the quantification of various modalities, including siRNA or oligonucleotides. The technique offers unique advantages of high specificity, fast method development, and robust assay performance. However, no LC-MS/MS-based method has been reported for the quantitative bioanalysis of ARCs. In this work, we developed a novel hybrid LC-MS/MS methodology for the quantification of ARCs using Ab-siRNA01, an antibody-siRNA conjugate, as the test compound. An antihuman IgG antibody was used as the capture antibody to selectively extract the target ARC analyte from the serum samples. The optimized hybrid LC-MS/MS method was successfully qualified for the quantitation of Ab-siRNA01 in mouse serum over the range of 6.70-3350 ng/mL. The developed method was used to support pharmacokinetic studies of Ab-siRNA01 in mice. This work is the first instance where a hybrid LC-MS/MS method was developed and applied to the quantification of antibody-siRNA conjugates. This novel methodology can also be applied to other ARCs and significantly facilitates their research and development.
- 25 August 2025
- Published by Taylor & Francis in Bioanalysis
- p. 1-15
Examining hybridization-based LC–MS methodologies for the bioanalysis of siRNA analytes
Hybridization-based LC-MS is rapidly emerging as a bioanalytical platform for oligonucleotides, particularly when both high sensitivity and high specificity are needed. When used to analyze single-stranded antisense oligonucleotide (ASO) therapeutics, the workflows are relatively well established, but the analysis of double-stranded small interfering RNA (siRNA) therapeutics presents additional challenges due to competition for binding from the sense strand. In the last two years, the authors have independently published extensively on hybridization-based LC-MS bioanalysis of siRNA therapeutics, and now we take a step back to evaluate the progress we have made and offer our thoughts on the future of this platform. We touch upon aspects of the sample preparation and analytical process that can either be improved upon, made more efficient, or expanded to maximize the information that can be gained from a single sample. Additionally, we discuss how hybridization-based LC-MS compares to other common oligonucleotide bioanalytical workflows, and its potential to become a frontline assay platform for use in supporting regulatory submissions. Overall, we are excited about the potential hybridization-based LC-MS has demonstrated as a bioanalytical platform and are eager to begin the conversation on where this workflow goes next.
- 25 August 2025
- Published by Taylor & Francis in Bioanalysis
- p. 1-15
Examining hybridization-based LC–MS methodologies for the bioanalysis of siRNA analytes
Hybridization-based LC-MS is rapidly emerging as a bioanalytical platform for oligonucleotides, particularly when both high sensitivity and high specificity are needed. When used to analyze single-stranded antisense oligonucleotide (ASO) therapeutics, the workflows are relatively well established, but the analysis of double-stranded small interfering RNA (siRNA) therapeutics presents additional challenges due to competition for binding from the sense strand. In the last two years, the authors have independently published extensively on hybridization-based LC-MS bioanalysis of siRNA therapeutics, and now we take a step back to evaluate the progress we have made and offer our thoughts on the future of this platform. We touch upon aspects of the sample preparation and analytical process that can either be improved upon, made more efficient, or expanded to maximize the information that can be gained from a single sample. Additionally, we discuss how hybridization-based LC-MS compares to other common oligonucleotide bioanalytical workflows, and its potential to become a frontline assay platform for use in supporting regulatory submissions. Overall, we are excited about the potential hybridization-based LC-MS has demonstrated as a bioanalytical platform and are eager to begin the conversation on where this workflow goes next.
- Open Access
- 4 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 12155-12163
Quantitative Determination of Click-Reactive Antisense Oligonucleotide and Its Reactivity in Rat Brains by Hybridization LC-MS/MS to Support Pretargeted PET Imaging
Antisense oligonucleotide (ASO) therapeutics are rapidly increasing in prevalence for the treatment of neurodegenerative diseases. A novel pretargeted positron emission tomography (PET) imaging methodology based on in vivo click chemistry was developed recently to assess ASO biodistribution in the brain. To validate the performance of the method, a sensitive, accurate, and reliable method to quantitatively determine the reactivity and distribution of click-reactive ASO in the brain is required. A major challenge is that the click-reactive ASO may undergo oxidation or rearrangement in vivo and lose reactivity to the TCO on the radiotracer. With their small mass differences, it is difficult to differentiate these unreactive degradants from the intact reactive ASO by LC-MS/MS. Here, we developed a novel postextraction analyte derivatization methodology utilizing conjugation of the click-reactive ASO, Malat1 ASO with a 1,2,4,5-methyltetrazine (MeTz) modification (Malat1 ASO-MeTz), with a TCO ligand (TCO-PEG4-DBCO) to differentiate the reactive and unreactive ASOs. The intact and reactive form of Malat1 ASO-MeTz was determined by LC-MS/MS analysis of the conjugation reaction product. A hybridization LC-MS/MS method that simultaneously quantifies Malat1 ASO-MeTz and Malat1 ASO over the range of 1.00-1000 ng/mL was also developed to determine the ASO distribution in rat brains. The methods were successfully applied to a pretargeted PET imaging study in rats. This is the first report that a postextraction analyte derivatization methodology was successfully developed for determining the reactive form and reactivity of click-reactive ASOs. The developed bioanalytical methodology will also significantly facilitate the evaluation of other radiotracers for pretargeted PET imaging.
- 4 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (23) , 12155-12163
Open AccessQuantitative Determination of Click-Reactive Antisense Oligonucleotide and Its Reactivity in Rat Brains by Hybridization LC-MS/MS to Support Pretargeted PET Imaging
Antisense oligonucleotide (ASO) therapeutics are rapidly increasing in prevalence for the treatment of neurodegenerative diseases. A novel pretargeted positron emission tomography (PET) imaging methodology based on in vivo click chemistry was developed recently to assess ASO biodistribution in the brain. To validate the performance of the method, a sensitive, accurate, and reliable method to quantitatively determine the reactivity and distribution of click-reactive ASO in the brain is required. A major challenge is that the click-reactive ASO may undergo oxidation or rearrangement in vivo and lose reactivity to the TCO on the radiotracer. With their small mass differences, it is difficult to differentiate these unreactive degradants from the intact reactive ASO by LC-MS/MS. Here, we developed a novel postextraction analyte derivatization methodology utilizing conjugation of the click-reactive ASO, Malat1 ASO with a 1,2,4,5-methyltetrazine (MeTz) modification (Malat1 ASO-MeTz), with a TCO ligand (TCO-PEG4-DBCO) to differentiate the reactive and unreactive ASOs. The intact and reactive form of Malat1 ASO-MeTz was determined by LC-MS/MS analysis of the conjugation reaction product. A hybridization LC-MS/MS method that simultaneously quantifies Malat1 ASO-MeTz and Malat1 ASO over the range of 1.00-1000 ng/mL was also developed to determine the ASO distribution in rat brains. The methods were successfully applied to a pretargeted PET imaging study in rats. This is the first report that a postextraction analyte derivatization methodology was successfully developed for determining the reactive form and reactivity of click-reactive ASOs. The developed bioanalytical methodology will also significantly facilitate the evaluation of other radiotracers for pretargeted PET imaging.
- 7 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (797) , eadl1732
PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry
Determination of a drug’s biodistribution is critical to ensure that it reaches the target tissue of interest. This is particularly challenging in the brain, where invasive sampling methods may not be possible. Here, we present a pretargeted positron emission tomography (PET) imaging methodology that uses bioorthogonal click chemistry to determine the distribution of an antisense oligonucleotide (ASO) in the brains of rats and nonhuman primates after intrathecal dosing of ASO. A PET tracer, [ 18 F]BIO-687, bearing a click-reactive trans -cyclooctene was developed and tested in conjunction with a test Malat1 ASO conjugated with a methyltetrazine group. PET imaging in rats demonstrated that the tracer had good kinetic properties for PET imaging in the rodent central nervous system and could react to form a covalent linkage with high specificity to the methyltetrazine-conjugated ASO in vivo. Furthermore, the amount of PET tracer reacted by cycloaddition with the methyltetrazine was determined to be dependent on the concentration of ASO-methyltetrazine in rat brain tissue, as determined by comparing the PET imaging signal with the liquid chromatography–mass spectrometry signal in the tissue homogenates. The approach was evaluated in cynomolgus macaques using both the Malat1 test ASO and a candidate therapeutic ASO, BIIB080, targeting the microtubule-associated protein tau ( MAPT ) gene. PET imaging showed favorable tracer kinetics and specific binding to both ASOs in nonhuman primate (NHP) brain in vivo. These results suggest that the PET imaging tracer [ 18 F]BIO-687 could show the distribution of intrathecally delivered ASOs in the rat and NHP brains.
- 7 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (797) , eadl1732
PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry
Determination of a drug’s biodistribution is critical to ensure that it reaches the target tissue of interest. This is particularly challenging in the brain, where invasive sampling methods may not be possible. Here, we present a pretargeted positron emission tomography (PET) imaging methodology that uses bioorthogonal click chemistry to determine the distribution of an antisense oligonucleotide (ASO) in the brains of rats and nonhuman primates after intrathecal dosing of ASO. A PET tracer, [ 18 F]BIO-687, bearing a click-reactive trans -cyclooctene was developed and tested in conjunction with a test Malat1 ASO conjugated with a methyltetrazine group. PET imaging in rats demonstrated that the tracer had good kinetic properties for PET imaging in the rodent central nervous system and could react to form a covalent linkage with high specificity to the methyltetrazine-conjugated ASO in vivo. Furthermore, the amount of PET tracer reacted by cycloaddition with the methyltetrazine was determined to be dependent on the concentration of ASO-methyltetrazine in rat brain tissue, as determined by comparing the PET imaging signal with the liquid chromatography–mass spectrometry signal in the tissue homogenates. The approach was evaluated in cynomolgus macaques using both the Malat1 test ASO and a candidate therapeutic ASO, BIIB080, targeting the microtubule-associated protein tau ( MAPT ) gene. PET imaging showed favorable tracer kinetics and specific binding to both ASOs in nonhuman primate (NHP) brain in vivo. These results suggest that the PET imaging tracer [ 18 F]BIO-687 could show the distribution of intrathecally delivered ASOs in the rat and NHP brains.
- Open Access
- 1 November 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 253, 116556
Analyte and probe melting temperature guided method development strategy for hybridization LC-MS/MS quantification of siRNAs
- 1 November 2024
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 253, 116556
Open AccessAnalyte and probe melting temperature guided method development strategy for hybridization LC-MS/MS quantification of siRNAs